hepionpharma.com (HEPA) - Koefisien utang jangka dawa marang modal

Hepion Pharmaceuticals (HEPA) is a biopharmaceutical player developing MASH therapies, where capital stability is maintained through strict testing expenditure limits and patents. Demand for hepatitis treatment is independent of economic conditions, meaning the business relies on medical outcomes. The share price retrospective demonstrates the 0.00 metric, however, the company has now closed all programs and completely ceased its research and development activities.

To assess the long-term solvency of Hepion Pharmaceuticals (HEPA), it is essential to analyze its liability structure. This indicator is calculated as the ratio of loans with a maturity of more than one year to total equity. By analyzing the dynamics of long-term debt to equity, an investor determines the business's degree of dependence on external financing. A low debt load confirms the company's stability within an independent product cycle. Stable demand for innovative drugs allows Hepion Pharmaceuticals to minimize risks by utilizing capital to advance research.